Payment overview · 2025
General Payments
$355.51
14 reported records · 10 companies
Healthcare provider profile · identity verified
Joseph Czvik, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN MARCOS, CA · NPI 1528084340
Verified facts
What the public records show
CMS Open Payments records show Joseph Czvik, MD received $355.51 in general payments during 2025 across 14 reported records.
TMS NeuroHealth Centers Inc. accounted for 37.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $133.84 | 37.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.64 | 14.5% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $28.42 | 8.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.30 | 7.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.68 | 6.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.01 | 5.6% | 1 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $19.81 | 5.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.69 | 5.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.58 | 5.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.54 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $355.51 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $133.84 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.64 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.64 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $28.42 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.30 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 369 | 107 |
| Losartan Potassium | Losartan Potassium | 276 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 65 |
| Trazodone Hcl | Trazodone Hcl | 188 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 53 |
| Omeprazole | Omeprazole | 169 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 45 |
| Metformin Hcl | Metformin Hcl | 145 | 41 |
| Furosemide | Furosemide | 144 | 39 |
| Lisinopril | Lisinopril | 141 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 138 | 44 |
| Gabapentin | Gabapentin | 120 | 34 |
| Ozempic | Semaglutide | 120 | 20 |
| Sertraline Hcl | Sertraline Hcl | 109 | 34 |
| Alprazolam | Alprazolam | 102 | 22 |
| Eliquis | Apixaban | 98 | 30 |
| Potassium Chloride | Potassium Chloride | 98 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 15 |
| Tramadol Hcl | Tramadol Hcl | 86 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 14 |
| Lorazepam | Lorazepam | 70 | 15 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 69 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 64 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 57 | 19 |
| Metformin Hcl Er | Metformin Hcl | 54 | 19 |
| Ibuprofen | Ibuprofen | 51 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 31 |
| Meloxicam | Meloxicam | 45 | 11 |
| Carvedilol | Carvedilol | 44 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 13 |
| Simvastatin | Simvastatin | 43 | 13 |
| Atenolol | Atenolol | 42 | 16 |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 26 |
| Allopurinol | Allopurinol | 40 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 12 |
| Montelukast Sodium | Montelukast Sodium | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | 12 |
| Chlorthalidone | Chlorthalidone | 38 | 12 |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Ketoconazole | Ketoconazole | 32 | 21 |
| Spironolactone | Spironolactone | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 18 |
| Acyclovir | Acyclovir | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 24 |
| Famotidine | Famotidine | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Estradiol | Estradiol | 24 | 13 |
| Glipizide Er | Glipizide | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Prednisone | Prednisone | 24 | 15 |
| Temazepam | Temazepam | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Verapamil Sr | Verapamil Hcl | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 15 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $355.51 · 14 records | TMS NeuroHealth Centers Inc. | CAPVAXIVE, Cologuard Collection Kit, EVENITY, Kerendia, MOUNJARO, Ozempic, Rybelsus, TMS NeuroHealth Centers Inc., TRELEGY ELLIPTA, ZEPBOUND, ZORYVE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error